A federal judge just invoked Star Trek in a $5 billion patent ruling against Moderna. Here is why the mRNA giant is heading ...

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

One panelist accused the F.D.A. of withholding data on potential harms. The advisers also are reviewing research on vaccines ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the ...

Global mRNA Synthesis and Manufacturing Market OverviewThe global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...

If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent ...

A new study shows that lipid nanoparticles restructure their membrane significantly after being absorbed into a cell and ...